Cover Image

CLEC5a-directed bispecific antibody for effective cellular phagocytosis

While antibody-dependent cellular phagocytosis mediated by activating Fcγ receptor is a key mechanism underlying many antibody drugs, their full therapeutic activities can be restricted by the inhibitory Fcγ receptor IIB (FcγRIIB). Here, we describe a bispecific antibody approach that harnesses phag...

Full description

Saved in:

Bibliographic Details
Main Authors:	Vivekananda Kedage (Author), Diego Ellerman (Author), Mingjian Fei (Author), Wei-Ching Liang (Author), Gu Zhang (Author), Eric Cheng (Author), Juan Zhang (Author), Yongmei Chen (Author), Haochu Huang (Author), Wyne P. Lee (Author), Yan Wu (Author), Minhong Yan (Author)
Format:	Book
Published:	Taylor & Francis Group, 2022-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Harnessing MerTK agonism for targeted therapeutics
by: Vivekananda Kedage, et al.
Published: (2020)

Low Expression of CLEC2B Indicates Poor Prognosis in Melanoma
by: Zhang Y, et al.
Published: (2023)

Dissecting the molecular basis of high viscosity of monospecific and bispecific IgG antibodies
by: Cholpon Tilegenova, et al.
Published: (2020)

Enhancement of antibody-dependent cellular phagocytosis is essential to the clearance of HIV-1 reservoirs in lymphoid organs
by: L. Shan
Published: (2019)

Bispecific antibodies in cancer immunotherapy
by: Eva Dahlén, et al.
Published: (2018)

Bispecific antibodies for viral immunotherapy
by: Elisabeth K. Nyakatura, et al.
Published: (2017)

Bispecific antibody drug conjugates: Making 1+1>2
by: Yilin Gu, et al.
Published: (2024)

Bispecific Antibodies Progression in Malignant Melanoma
by: Juan Tang, et al.
Published: (2022)

A pivotal decade for bispecific antibodies?
by: Marlena Surowka, et al.
Published: (2024)

Bispecific antibodies: design, therapy, perspectives
by: Sedykh SE, et al.
Published: (2018)

Developability considerations for bispecific and multispecific antibodies
by: Alaa Amash, et al.
Published: (2024)

Pharmacokinetic evaluation of radiolabeled intraocular anti‐CLEC14a antibody in preclinical animal species and application in humans
by: Sohyun Park, et al.
Published: (2022)

Assessment of the role of afucosylated glycoforms on the in vitro antibody-dependent phagocytosis activity of an antibody to Aβ aggregates
by: Allyson Kwiatkowski, et al.
Published: (2020)

Selenoprotein K Is Essential for the Migration and Phagocytosis of Immature Dendritic Cells
by: Huan Xia, et al.
Published: (2022)

Enhancing the immunogenicity of cancer vaccines by harnessing CLEC9A
by: M. H. Lahoud, et al.
Published: (2022)

Bispecific antibodies in cancer therapy: Target selection and regulatory requirements
by: Yanze Sun, et al.
Published: (2023)

Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?
by: Jingjing Zhang, et al.
Published: (2022)

Bispecific Antibodies in Cancer Immunotherapy: A Novel Response to an Old Question
by: Camila Ordóñez-Reyes, et al.
Published: (2022)

Rational selection of building blocks for the assembly of bispecific antibodies
by: Danyang Gong, et al.
Published: (2021)

Intein mediated high throughput screening for bispecific antibodies
by: Tim Hofmann, et al.
Published: (2020)

Bispecific antibodies for non-Hodgkin's lymphomas and multiple myeloma
by: Omar Castaneda-Puglianini, et al.
Published: (2021)

Epitope mapping of anti-drug antibodies to a clinical candidate bispecific antibody
by: Arthur J. Schick, et al.
Published: (2022)

T Cell Bispecific Antibodies: An Antibody-Based Delivery System for Inducing Antitumor Immunity
by: Daisuke Kamakura, et al.
Published: (2021)

Manufacturability and functionality assessment of different formats of T-cell engaging bispecific antibodies
by: Han Ping Loh, et al.
Published: (2023)

Dose escalation PET imaging for safety and effective therapy dose optimization of a bispecific antibody
by: Yan Wang, et al.
Published: (2020)

Cell Therapy, Bispecific Antibodies and other Immunotherapies Against Cancer
Published: (2023)

Bispecific antibody-derived molecules to target persistent HIV infection
by: Jeffrey L. Nordstrom, et al.
Published: (2022)

Stepping forward: T-cell redirecting bispecific antibodies in cancer therapy
by: Xiaojing Qin, et al.
Published: (2024)

Bispecific antibodies: a novel approach for targeting prominent biomarkers
by: Akshita Gupta, et al.
Published: (2020)

The eIg technology to generate Ig-like bispecific antibodies
by: Lennart Kühl, et al.
Published: (2022)

Bispecific Antibodies in Lung Cancer: A State-of-the-Art Review
by: Atulya Aman Khosla, et al.
Published: (2023)

Bispecific Antibodies: A Novel Approach for the Treatment of Solid Tumors
by: Luigi Liguori, et al.
Published: (2022)

Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies
by: Gabriele Antonarelli, et al.
Published: (2021)

Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer
by: Tian Huan, et al.
Published: (2023)

Phagocytosis Main Key of Immune System
Published: (2023)

Generating a Bispecific Antibody Drug Conjugate Targeting PRLR and HER2 with Improving the Internalization
by: Hui-Fang Zong, et al.
Published: (2022)

Kinetic analysis of ternary and binary binding modes of the bispecific antibody emicizumab
by: Stefanie Mak, et al.
Published: (2023)

An integrated approach for characterizing immunogenic responses toward a bispecific antibody
by: Sivan Cohen, et al.
Published: (2021)

Implications of CLEC3B as a Prognostic Marker in Oral Squamous Cell Carcinoma
by: Zehra Ahmed, et al.
Published: (2024)

Implications of CLEC3B as a Prognostic Marker in Oral Squamous Cell Carcinoma
by: Zehra Ahmed, et al.
Published: (2024)